In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC

Our study proposes a diagnostic shift from static biomarker quantification to assessing active immune pathways, providing more precise ICI treatment. This functional concept applies to tiny lung biopsies and can be extended to further immune checkpoints. Accordingly, our results indicate concerted ICI resistance mechanisms, highlighting the need for combination diagnostics and therapies.

Authors

Institutions

Publication Details

Journal
Journal of Thoracic Oncology
Published
2024-12-30
DOI
https://doi.org/10.1016/j.jtho.2024.12.026
Citations
6
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
1.70

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC

Max Backman, Klas Kärre, J Friedrich, Erika Broström et al.
6 citations
Journal of Thoracic Oncology
Cancer Immunotherapy and Biomarkers
1.70
article

In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC

Max Backman, Klas Kärre, J Friedrich, Erika Broström, Lars Muhl, Cecilia Lindskog, Amanda Lindberg, Artur Mezheyeuski, Hans Brunnström, Patrick Micke, Johanna Sofia Margareta Mattsson, Miklós Gulyás, Neda Hekmati, Carina Strell, Louise Hellberg, Johan Isaksson, Johan Botling, Rebecca Artursson, Hui Yu
article en
6 citations

Abstract

Our study proposes a diagnostic shift from static biomarker quantification to assessing active immune pathways, providing more precise ICI treatment. This functional concept applies to tiny lung biopsies and can be extended to further immune checkpoints. Accordingly, our results indicate concerted ICI resistance mechanisms, highlighting the need for combination diagnostics and therapies.

Journal of Thoracic OncologyVol. 20(5)
Uppsala University (SE), Lund University (SE), Karolinska Institutet (SE), Vall d'Hebron Institut de Recerca (ES), Integrated Cardio Metabolic Centre (SE), Vall d'Hebron Hospital Universitari (ES), University of Gothenburg (SE)
Trond Mohn stiftelse, Cancerfonden, Vetenskapsrådet, Akademiska Sjukhuset, Uppsala Universitet
Openalex Percentile: Top 12%
Cancer Immunotherapy and Biomarkers
1.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.